Open Actively Recruiting

Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

About

Brief Summary

Reduction of elevated pressure in the eye (Intraocular pressure, or 'IOP') with eye drop medications has been shown to be effective in delaying or preventing the progression of glaucoma, and it is the only proven method for reducing the risk of glaucomatous visual field loss.

This study is being conducted to determine how well DE-126 ophthalmic solution works (efficacy) in safely lowering IOP when dosed as topical eyedrops. This study will evaluate the safety and efficacy of DE-126, ophthalmic solution in subjects with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT). The IOP will be measured at 3 different times throughout the day, over 4 total visits during a 3-month treatment period (with up to 4 extra weeks observation if the patient must stop taking current eye drops to lower IOP). Safety assessments will be done throughout the study, including ocular signs and symptoms, and vital signs. While the most important time-point to measure IOP in this study and evaluate efficacy will be at the final study visit (month 3), IOP values will also be evaluated at other visits throughout the 3-month treatment period.

Primary Purpose
Treatment
Study Type
Interventional
Phase
Phase 2

Eligibility

Gender
All
Healthy Volunteers
No
Minimum Age
18 Years
Maximum Age
N/A

Inclusion Criteria:

  • Have been diagnosed of POAG or OHT in both eyes, or one eye with OAG and other with OHT
  • Completed the required wait/washout period
  • Qualifying Day 1 IOP measurement at 3 time-points in both eyes

Exclusion Criteria:

  • Females who are pregnant, nursing, or planning a pregnancy
  • Subjects who cannot safely discontinue use of ocular hypotensive medications during the wait/washout period.
  • History of ocular surgery specifically intended to lower IOP in either eye. Laser iridotomy in history is allowed
  • Presence of advanced glaucoma in either eye

Join this Trial

Contact our clinical trial navigators for opportunities that may be suitable for you
Study Stats
Protocol No.
20-002104
Category
Ophthalmology
Principal Investigator
Contact
Connie Zhen
Location
  • UCLA Westwood
For Providers
NCT No.
NCT04742283
For detailed technical eligibility, visit ClinicalTrials.gov.